Vitrafy Life Sciences (VFY) investor relations material

Industry context and challenges

• Cryopreservation is foundational to healthcare, supporting IVF, blood, plasma, cell & gene therapies, and animal reproduction sectors.

• Existing technology is outdated, expensive, lacks intelligence, and often relies on harmful materials like liquid nitrogen.

• US blood supply shortages since 2020 highlight the need for scalable, advanced solutions.

• Personalized medicine and cell/gene therapies require improved cryopreservation for quality and scalability.

• Most manufacturers use non-optimized freeze profiles and lack critical process data, increasing risk of failure.

Technology, solution overview, and commercialization strategy

• Developed a smart, connected cryopreservation ecosystem combining hardware (Guardion Freezer, Thawing Units) and LifeChain software for traceability, quality, and workflow digitization.

• Hardware innovation includes a mobile, non-liquid nitrogen freezing device with low power needs, deployable anywhere with power.

• LifeChain software standardizes quality, enables traceability, digitizes workflows, and connects third-party devices.

• Commercialization uses a managed service, recurring revenue model rather than one-off equipment sales.

• Smart consumables and end-to-end connectivity are integrated for optimized preservation and transport.

Market focus, applications, and partnerships

• Targeting animal reproduction, blood products, and cell/gene therapy, with initial focus on North America and global reach.

• Over 2,200 animal health collection sites and ~8,000 points in blood and cell/gene therapy supply chain are addressable.

• Secured a commercial agreement with a global leader covering about 50% of the animal reproduction market.

• Blood platelets targeted due to high wastage and critical need, with successful U.S. Army study milestones.

• Early revenue and data from animal market de-risk human health market entry.